For differential diagnosis within the subgroup of gliomas, patients with oligodendroglioma characterized by an IDH mutation and a 1p/19q co-deletion [1] frequently exhibit a considerably higher amino acid uptake than patients with IDH-mutant astrocytomas [37]. The gene discussed is IDH2; the disease is central nervous system cancer.